References
Kuppers R, Duhrsen U, Hansmann ML (2014) Pathogenesis, diagnosis, and treatment of composite lymphomas. Lancet Oncol 15(10):e435–e446. doi:10.1016/S1470-2045(14)70153-6
Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1):25–38. doi:10.1016/j.ccr.2011.06.003
Couronne L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 366(1):95–96. doi:10.1056/NEJMc1111708
Cheminant M, Bruneau J, Kosmider O, Lefrere F, Delarue R, Gaulard P, Radford I, Derrieux C, Hermine O, Lemonnier F (2015) Efficacy of 5-Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol 168(6):913–916. doi:10.1111/bjh.13170
Sakata-Yanagimoto M (2015) Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol. doi:10.1007/s12185-015-1738-8
Acknowledgments
This work was supported by the Grants-in-Aid for Scientific Research (KAKENHI) (25461407 to M. S.-Y., 24390241, 15401504 to S.C.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Rights and permissions
About this article
Cite this article
Sakata-Yanagimoto, M., Yokoyama, Y., Muto, H. et al. A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms. Ann Hematol 95, 829–830 (2016). https://doi.org/10.1007/s00277-016-2612-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2612-3